NVO Sep 2024 145.000 call
| Previous close | 2.9700 |
| Open | 2.9200 |
| Bid | 2.7000 |
| Ask | 2.8500 |
| Strike | 145.00 |
| Expiry date | 2024-09-20 |
| Day's range | 2.9200 - 2.9200 |
| Contract range | N/A |
| Volume | |
| Open interest | 603 |
BloombergInvestors Pile Into Amgen in Search of Next Obesity Drug Payout
(Bloomberg) -- Investors who may have missed out on the blistering rally in Eli Lilly & Co. and Novo Nordisk A/S are once again taking a chance with Amgen Inc.Most Read from BloombergTruce Talks Drag as Hamas Hits Israel Crossing in Deadly AttackJudge Threatens Trump With Jail Over Gag Order ViolationsAt $2 Million Per Minute, Treasuries Mint Cash Like Never BeforeTreasury Rally Risks Running Into a $125 Billion Brick WallBuffett Praises Apple After Trimming It, Drops Paramount StakeThe shares s
Yahoo FinanceAmgen's peek at its GLP-1 drug trial results heightens competition in obesity market
Competition is heating up in the GLP-1 space as Amgen gets closer to the finish line with its candidate.
Insider MonkeyNovo Nordisk A/S (NYSE:NVO) Q1 2024 Earnings Call Transcript
Novo Nordisk A/S (NYSE:NVO) Q1 2024 Earnings Call Transcript May 2, 2024 Novo Nordisk A/S misses on earnings expectations. Reported EPS is $0.7 EPS, expectations were $0.77. NVO isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day! And thank […]
